Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on PK of Apatinib Mesylate
NCT04341090Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Rivoceranib in gastric cancer (GC) (6 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from Time 0 to Last Measurable Concentration and 1 more. Started May 2020; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04341090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341090.